Validation of Donor-Derived Cell-Free DNA (Dd-cfDNA) for Kidney Transplant Monitoring
Start Date
9/8/2025
Completion Date
12/1/2025
Summary
The goal of this observational study is to learn if the donor-derived cell-free DNA (dd-cfDNA) test can assess rejection in kidney transplant recipients. Participants will have blood and urine collected at their study visit. Researchers will compare results of the GraftAssureDx to rejection detected by standard-of-care graft biopsies.
Eligibility Criteria
Age Range: 18 years to No maximum
Interventions
donor-derived cell-free DNA test
Conditions
Locations
University of Southern California Keck School of Medicine
Los Angeles, California 90033
United States
Mayo Clinic in Florida
Jacksonville, Florida 32224
United States
Tampa General Hospital
Tampa, Florida 33606
United States
Cleveland Clinic
Cleveland, Ohio 44195
United States
University of Pittsburgh Medical Center
Pittsburgh, Pennsylvania 15213
United States
Vanderbilt University Medical Center
Nashville, Tennessee 37232
United States
Baylor, Scott & White Research Institute
Dallas, Texas 75246
United States
Intermountain Health
Murray, Utah 84107
United States
Institute of Immunology - Transplantation Immunology
Heidelberg, Baden-Wurttemberg 69120
Germany
Charite Universitatsmedizin
Berlin, 10117
Germany